Our Pipeline - ArriVent Biopharma

CandidateCand	IndicationInd	DiscoveryDisc
Furmonertinib Oral, brain penetrant, EGFR mutation selective inhibitor	NSCLC with EGFR Exon 20 insertion mutations FURVENT Furmo-004	NSCLC with EGFR Exon 20 insertion mutations FURVENT Furmo-004 Phase 3Ph 3
	NSCLC with other EGFR mutations FURTHER Furmo-002	NSCLC with other EGFR mutations FURTHER Furmo-002 Phase 1bPh 1b
	NSCLC with HER2 Exon 20 insertion mutations FURTHER Furmo-002	NSCLC with HER2 Exon 20 insertion mutations FURTHER Furmo-002 Phase 1bPh 1b
ARR-002 Undisclosed	Solid Tumors	Solid Tumors DiscoveryDisc

Furmonertinib

Mutational activation of the epidermal growth factor receptor (EGFR) is a common and early event in the development of non-small cell lung cancer (NSCLC) and confers oncogene dependency on the growth and proliferation of cancer cells. EGFR activating mutations are present in approximately 15% of NSCLC. Patients with NSCLC containing EGFR activating mutations are also particularly prone to the development of brain metastases, with 50% to 60% developing central nervous system (CNS) metastases over the course of their disease. Despite initial clinical response to currently approved EGFR inhibitors, patients with advanced EGFR mutated NSCLC inevitably acquire resistance mechanisms and progress at some point during treatment; therefore, there is the need for more effective, tolerable treatments.

Furmonertinib is an oral, highly brain-penetrant, broadly active mutation-selective EGFR inhibitor that targets both classical (exon 19 deletion and L858R) and uncommon EGFR mutations, including exon 20 insertion mutations as well as HER2 exon 20 insertion mutations. Furmonertinib is approved in China as an anticancer therapy for patients with NSCLC who have an EGFR T790M mutation, and more recently, as a first-line treatment in patients with NSCLC who have classical EGFR mutations. Furmonertinib is being developed in China by Allist Pharmaceuticals and in the rest of the world by ArriVent Biopharma.

ArriVent is studying furmonertinib globally in patients with NSCLC with EGFR mutations and HER2 Exon 20 insertion mutations.

ARR-002

We are partnered with Aarvik Therapeutics to advance a novel cancer therapeutic agent. As part of our agreement, Aarvik is responsible for the discovery and preclinical validation of the novel molecule, which is based on their unique modular platform that combines multiple target mechanisms. The ArriVent team will lead development and commercialization of the ARR-002 program.